Ionis grants Recordati ex-U.S. rights to zilganersen for Alexander disease while retaining U.S. comm

Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridem

Ionis wins FDA approval to expand Tryngolza to severe hypertriglyceridemia, opening a broader market

Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutra

The U.S. Food and Drug Administration (FDA) approved on Wednesday Ionis Pharmaceuticals, Inc.'s (NAS

Ionis wins FDA approval for Tryngolza in severe hypertriglyceridemia and signs a Recordati licensing

Leerink Partners analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outpe

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS)

- Recordati brings deep rare disease expertise and proven capabilities in commercialization, access

Leerink Partners analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outpe

TD Cowen analyst Yaron Werber reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maint

Intellia shares rise after new Phase 3 lonvo-z data showed significant reductions in HAE attacks and

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS)

Citigroup analyst Eric Joseph initiates coverage on Ionis Pharmaceuticals (NASDAQ:IONS) with a Bu

Biogen shares slip after mixed Phase 2 Alzheimer's data, but analysts remain optimistic on diran

Biogen Inc. (NASDAQ:BIIB) today announced compelling topline results from the Phase 2 CELIA study ev

GSK partnered with Sino Biopharmaceutical to advance hepatitis B drug bepirovirsen in China while la

RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and

Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) raises FY2026 sales outlook from $800.000 million-$825.000 milli

Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.30) per share which beat the an

TD Cowen analyst Yaron Werber maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers

Canaccord Genuity analyst Gary Nachman initiates coverage on Ionis Pharmaceuticals (NASDAQ:IONS)

Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweigh

– New data highlight potential treatment benefit across multiple AxD symptom domains, reinforcing zi

Ionis Pharmaceuticals cuts Tryngolza price ahead of sHTG decision, with analysts seeing stronger sal

Ark Invest, led by Cathie Wood, issued another "Big Ideas" list on Wednesday, sharing themes

Pharvaris reports Phase 3 data showing its oral HAE treatment delivers rapid relief, fewer second do

Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 202

Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, thr

Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, p

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and s

Ionis Pharmaceuticals rose 2.38% after hours following a planned stock sale by its chief scientific

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts a

William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport